Success with health and agriculture: Bayer raises targets | News Ro

Crisis-proof: Sales of crop protection and genetically modified seeds . (Photo: AP)

Tuesday 31 July 2012 2012-07-31 09:21:11

With two strong pillars of the stumps Dax heavyweight Bayer largely undeterred by the uncertainty of the debt crisis: bring solid results from the Health Care and the Group Cropscience growth in sales and profits .

draw on Legal Problems in the U.S. Bayer?s net income. (Photo: DAPD)

The pharmaceutical and chemical company Bayer has increased after a strong quarter operationally, the forecast for the full year. In the second quarter, the Group increased its sales by ten percent to 10.2 billion euros. The growth of the DAX companies, in particular, leads to strong growth in its agricultural chemicals business ?CropScience?, and the robust performance in the health sector ?Health Care? back.

-tax profit (EBITDA) rose year on year by 6.7 percent to almost 2.2 billion euros. The gain, however, was due to high special charges ? such as for litigation and renovation work -. Back by 34 percent to ? 494 million

2012 was to be expected in earnings before interest, taxes, depreciation, amortization and special items (EBITDA) with an increase in the high single digit percentage range, Bayer announced at its headquarters in Leverkusen with. So far, only a slight improvement had been promised. The sales should be adjusted in 2012 to increase by four to five per cent to 39 to 40 billion ?. Bayer previously had targeted an increase of around three percent.

most important engine of growth continued to be the agricultural chemical business for the Bayer-year forecast as well as for increasing the health sector. Given that even in economically sensitive plastics business ?Material Science? so far shows no signs of burglary, the CEO Marijn Dekkers was confident for the second half. In addition, Bayer is also benefiting from a group for the very favorable currency environment.

thrombosis risk in the U.S.

The only

larger shadow on the quarterly results were the provisions for the legal battle around contraceptives, which are marketed under the product name Yaz and Yasmin. The precautionary covered sums expressed in millions of dollars to net profits significantly.

In the United States against Bayer currently has more than 12,000 lawsuits pending. The plaintiffs are suing Bayer, have warned against insufficient thrombosis risks of the drug.

Although Bayer

insured against product liability risks, but the coverage is now exhausted, so the company had to make additional provisions.

Bayer is currently seeking comparisons with individual applicants who are suffering from venous blood clots ? such as deep vein thrombosis or pulmonary embolism. Such diseases affect Bayer, according to preliminary findings, only approximately half of the complaints.

So far, Bayer has

compared with 1877 applicants, the payments for this amount to approximately 403 million U.S. dollars.

Bayer believes that with adequate provision for the majority of cases, care has been taken. Further charges are therefore not completely ruled out.

Sport

Source: http://news-ro.com/success-with-health-and-agriculture-bayer-raises-targets/

greystone sidney crosby at the drive in alternative minimum tax modeselektor gran torino gloria steinem